The appropriate role of cost-effectiveness in determining device coverage: a case study of drug-eluting stents
| Autor: | S. Fearn, Liesl M. Cooper, Brian G. Firth |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Cost effectiveness business.industry Health Policy media_common.quotation_subject Cost-Benefit Analysis Advisory Committees Nice Drug-Eluting Stents Health outcomes State Medicine United Kingdom Surgery Reimbursement Mechanisms Risk analysis (engineering) Excellence Blunt instrument Organizational Case Studies Medicine Quality-Adjusted Life Years business computer health care economics and organizations media_common computer.programming_language |
| Zdroj: | Health affairs (Project Hope). 27(6) |
| ISSN: | 1544-5208 |
| Popis: | The use of incremental cost-effectiveness ratios based on quality-adjusted life-years (QALYs) as a critical determinant of what should be covered by a health system is a growing trend. This presents challenges when applied to rapidly evolving technologies. The case study here focuses on the example of drug-eluting stents and the four-year change in cost-effectiveness as determined by the U.K. National Institute for Health and Clinical Excellence (NICE). We contend that classic cost-effectiveness as a blunt instrument for determining what should be covered may lead to erroneous conclusions when a broader perspective and the impact on health outcomes and costs are considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|